Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure
about
Apoptosis in myocardial ischaemia and infarctionDirect interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growthOngoing controversies surrounding cardiac remodeling: is it black and white-or rather fifty shades of gray?Regulation of Abro1/KIAA0157 during myocardial infarction and cell death reveals a novel cardioprotective mechanism for Lys63-specific deubiquitinationNfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failureThe miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivoActivated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivoAlpha B-crystallin suppresses pressure overload cardiac hypertrophyThe transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells but is specific to the hypertrophic effect of urocortinFoxo3a inhibits cardiomyocyte hypertrophy through transactivating catalaseDirect and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.Regulation of calcineurin through transcriptional induction of the calcineurin A beta promoter in vitro and in vivo.Calcineurin protects the heart in a murine model of dilated cardiomyopathy.Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarctionConstitutively active calcineurin induces cardiac endoplasmic reticulum stress and protects against apoptosis that is mediated by alpha-crystallin-B.Critical role for death-receptor mediated apoptotic signaling in viral myocarditis.Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload.Calcineurin and hypertrophic heart disease: novel insights and remaining questions.FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress.Calcineurin and cardiac hypertrophy: where have we been? Where are we going?Beneficial effects of adenylyl cyclase type 6 (AC6) expression persist using a catalytically inactive AC6 mutant.Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure.Myocardial adaptation of energy metabolism to elevated preload depends on calcineurin activity : a proteomic approach.Human herpesvirus 8-encoded vGPCR activates nuclear factor of activated T cells and collaborates with human immunodeficiency virus type 1 Tat.Compensatory renal hypertrophy following uninephrectomy is calcineurin-independent.Isoform-specific dephosphorylation of dynamin1 by calcineurin couples neurotrophin receptor endocytosis to axonal growth.Calcineurin A-alpha but not A-beta is required for normal kidney development and functionO-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.TRPC4α and TRPC4β Similarly Affect Neonatal Cardiomyocyte Survival during Chronic GPCR Stimulation.TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.Anchoring proteins as regulators of signaling pathways.Myocardial AKT: the omnipresent nexus.Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy.Calcineurin activates cytoglobin transcription in hypoxic myocytes.Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.Chronic exercise downregulates myocardial myoglobin and attenuates nitrite reductase capacity during ischemia-reperfusion.Novel Ser/Thr protein phosphatases in cell death regulationApoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling.
P2860
Q22242031-456A5B09-6A07-464E-AC7E-08341A7C7E34Q24322716-9C1EF898-1E44-43B4-A052-C5396B27FD73Q26800197-868CE35C-43C2-442D-A85E-780812980346Q28116438-9C6A86DE-1EF9-438F-A404-CC8BC7E840FAQ28118235-B43DB7E6-11D0-442F-B5CA-7502C95413BBQ28118639-2A1783F7-71F4-489E-B336-DDD3E79D2F61Q28360110-71C0C3EE-B495-406F-A99C-D2D09682C2A4Q28511213-DE058E7A-8D88-4CDF-B41F-A7FEC64AF130Q28571805-B6933FC1-8230-415F-B6E9-5FBC42E88276Q28572612-F5899235-A77A-433D-9906-6FC47E3EA9A0Q28575707-C355E375-BB91-4417-ABD2-E93BEFCE64BCQ33713890-7C59CA5C-C643-4EBD-8DBD-87E37AF6C89CQ33925316-2C12D619-7F4E-43BB-A90B-F19C5A28FD8CQ33936214-D9E01F68-77D8-4ACB-A980-B53CBF38D833Q34038333-D94F2CE5-F017-411A-AF8E-4B2FF7657025Q34111821-E5F14C90-B8EF-4B1E-9591-D3CEC01357FBQ34276711-A404789A-333B-4D85-830F-14565713D65DQ34362593-677C4A5B-CFBA-4D66-8D41-0A0D4D617295Q34498911-82C2A45D-41DF-4DFB-9C0F-77F708129712Q34581528-B4AD80E3-F06C-4F89-B4D0-49FF7FD7F933Q34606366-E5C00D3D-F61D-4D79-8A2C-59DB1B4F9A2EQ34641729-A4B19F7B-3D3E-4264-A3CA-2D892F54C1E5Q34700987-11D90EA2-4FF6-479D-A6AC-E023393CD22BQ34892203-9221B52F-4277-4A57-8A09-F915F0EDAC69Q34901592-7B4B2D15-A1C5-44AB-808A-F010531E747EQ34976938-E742B4BF-FE31-4DDC-AD8F-47D853FD7C85Q34998348-A593ED08-DF10-4681-9202-8D8F63E642F4Q35059263-5A8C2020-BF83-4D06-8418-655AC7957F79Q35103375-BC757A1F-3933-4C03-B84E-49D2AAE0A8B0Q35994150-AA06D9F0-4BC3-4490-BDCC-D3583F53AE9CQ36228290-815B1D25-4271-4F60-BC4A-20AD87274A63Q36275375-231F6CAA-5668-4045-A315-AE8A97CB026DQ36430063-30F3D880-57A8-48EA-AD93-6C693F15989EQ36908289-F237FA4E-60CE-4783-A5FD-F4C3A74B9690Q37101616-2BDAA05E-7C12-4B66-B452-2337F64F9D96Q37155441-92132D26-3F92-4B09-9993-F9CEAF9CF6E2Q37175524-4D4A6B12-FAD0-4CFC-A7C6-1AC1755B0621Q37238807-7B56B129-BE1B-423E-A19C-4ABFAFB6DB99Q37256583-44A6E1AF-D8E6-40B5-A1C9-AC18D7814A1BQ37263689-30EDFCD3-BE60-4CD2-AF2E-9680F2F28125
P2860
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@ast
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@en
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@nl
type
label
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@ast
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@en
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@nl
prefLabel
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@ast
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@en
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@nl
P2093
P356
P1433
P1476
Calcineurin-mediated hypertrop ...... model of dilated heart failure
@en
P2093
G Condorelli
L J De Windt
R N Kitsis
P304
P356
10.1161/01.RES.86.3.255
P407
P577
2000-02-01T00:00:00Z